Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo

Nucleic Acids Research

Volumn 47, Issue 3, 2019, Pages 1082-1096

  Biscans, Annabelle ^a   Coles, Andrew ^a   Haraszti, Reka ^a   Echeverria, DImas ^a   Hassler, Matthew ^a   Osborn, Maire ^a   Khvorova, Anastasia ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LIPID; SMALL INTERFERING RNA; BEHENIC ACID; CARBOCYANINE; CYANINE DYE 3; FATTY ACID; FLUORESCENT DYE; PHOSPHORYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; GENE DELIVERY SYSTEM; GENE FUNCTION; GENE SILENCING; HYDROPHOBICITY; IN VIVO STUDY; INTRACELLULAR TRANSPORT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYNTHESIS; TISSUE DISTRIBUTION; ANIMAL; CHEMISTRY; KIDNEY; LIVER; METABOLISM; RNA INTERFERENCE;

ANIMALS; CARBOCYANINES; CHOLESTEROL; FATTY ACIDS; FEMALE; FLUORESCENT DYES; KIDNEY; LIPIDS; LIVER; MICE; PHOSPHORYLCHOLINE; RNA INTERFERENCE; RNA, SMALL INTERFERING; TISSUE DISTRIBUTION;

EID: 85065824816     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gky1239     Document Type: Article

References (51)

1. Zhou, J., Shum, K.-T., Burnett, J.C. and Rossi, J.J. (2013) Nanoparticle-based delivery of RNAi therapeutics: progress and challenges. Pharmaceuticals, 6, 85-107.
2. Nair, J.K., Willoughby, J.L.S., Chan, A., Charisse, K., Alam, M.R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel'in, A.V., Milstein, S. et al. (2014) Multivalent N-Acetylgalactosamine-Conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. JACS, 136, 16958-16961.
3. Zimmermann, T.S., Karsten, V., Chan, A., Chiesa, J., Boyce, M., Bettencourt, B.B., Hutabarat, R., Nochur, S., Vaishnaw, A. and Gollob, J. (2017) Clinical proof of concept for a novel hepatocyte-targeting GalNAc-siRNA conjugate. Mol. Ther., 25, 71-78.
4. Hassler, M.R., Turanov, A.A., Alterman, J.F., Haraszti, R.A., Coles, A.H., Osborn, M.F., Echeverria, D., Nikan, M., Salomon, W.E., Roux, L. et al. (2018) Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo. Nucleic Acids Res., 46, 2185-2196.
5. Nair, J.K., Attarwala, H., Sehgal, A., Wang, Q., Aluri, K., Zhang, X., Gao, M., Liu, J., Indrakanti, R., Schofield, S. et al. (2017) Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates. Nucleic Acids Res., 45, 10969-10977.
6. Foster, D.J., Brown, C.R., Shaikh, S., Trapp, C., Schlegel, M.K., Qian, K., Sehgal, A., Rajeev, K.G., Jadhav, V., Manoharan, M. et al. (2018) Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates. Mol. Ther., 26, 708-717.
7. Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J. et al. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 432, 173-178.
8. Allerson, C.R., Sioufi, N., Jarres, R., Prakash, T.P., Naik, N., Berdeja, A., Wanders, L., Griffey, R.H., Swayze, E.E. and Bhat, B. (2005) Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem., 48, 901-904.
9. Nallagatla, S.R. and Bevilacqua, P.C. (2008) Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner. RNA, 14, 1201-1213.
10. Jackson, A.L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J.M., Lim, L., Karpilow, J., Nichols, K. et al. (2006) Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA, 12, 1197-1205.
11. Geary, R.S., Norris, D., Yu, R. and Bennett, C.F. (2015) Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug. Deliv. Rev., 87, 46-51.
12. Eckstein, F. (2002) Developments in RNA chemistry, a personal view. Biochimie, 84, 841-848.
13. Ma, J.B., Yuan, Y.R., Meister, G., Pei, Y., Tuschl, T. and Patel, D.J. (2005) Structural basis for 5'-end-specific recognition of guide RNA by the A. fulgidus Piwi protein. Nature, 434, 666-670.
14. Frank, F., Sonenberg, N. and Nagar, B. (2010) Structural basis for 5'-nucleotide base-specific recognition of guide RNA by human AGO2. Nature, 465, 818-822.
15. Haraszti, R.A., Roux, L., Coles, A.H., Turanov, A.A., Alterman, J.F., Echeverria, D., Godinho, B.M., Aronin, N. and Khvorova, A. (2017) 5′-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo. Nucleic Acids Res., 45, 7581-7592.
16. Parmar, R., Willoughby, J.L.S., Liu, J., Foster, D.J., Brigham, B., Theile, C.S., Charisse, K., Akinc, A., Guidry, E., Pei, Y. et al. (2016) 5′-(E)-Vinylphosphonate: a stable phosphate mimic can improve the RNAi activity of siRNA-GalNAc conjugates. Chembiochem., 17, 987-989.
17. Rajeev, K.G., Nair, J.K., Jayaraman, M., Charisse, K., Taneja, N., O'Shea, J., Willoughby, J.L.S., Yucius, K., Nguyen, T., Shulga-Morskaya, s. et al. (2015) Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-Acetylgalactosamine elicits robust gene silencing in vivo. Chembiochem., 16, 903-908.
18. Matsuda, S., Keiser, K., Nair, J.K., Charisse, K., Manoharan, R.M., Kretschmer, P., Peng, C.G., Kel'in, A.V., Kandasamy, P., Willoughby, J.L.S. et al. (2015) siRNA conjugates carrying sequentially assembled trivalent N-Acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem. Biol., 10, 1181-1187.
19. Prakash, T.P., Graham, M.J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H.F. et al. (2014) Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res., 42, 8796-8807.
20. Tanowitz, M., Hettrick, L., Revenko, A., Kinberger, G.A., Prakash, T.P. and Seth, P.P. (2017) Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes. Nucleic Acids Res., 45, 12388-12400.
21. Huang, H. (2017) Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics. Mol. Ther. Nucleic Acids, 6, 116-132.
22. Osborn, M.F. and Khvorova, A. (2018) Improving siRNA delivery In vivo through lipid conjugation. Nucleic Acid Ther., 28, 128-136.
23. Wolfrum, C., Shi, S., Jayaprakash, K.N., Jayaraman, M., Wang, G., Pandey, R.K., Rajeev, K.G., Nakayama, T., Charrise, K., Ndungo, E.M. et al. (2007) Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol., 25, 1149-1157.
24. Nishina, K., Unno, T., Uno, Y., Kubodera, T., Kanouchi, T., Mizusawa, H. and Yokota, T. (2008) Efficient in vivo delivery of siRNA to the liver by conjugation of α-tocopherol. Mol. Ther., 16, 734-740.
25. Yuan, H., Lanting, L., Xu, Z.-G., Li, S.-L., Swiderski, P., Putta, S., Jonnalagadda, M., Kato, M. and Natarajan, R. (2008) Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes. Am. J. Physiol. Renal Physiol., 295, F605-F617.
26. Khan, T., Weber, H., DiMuzio, J., Matter, A., Dogdas, B., Shah, T., Thankappan, A., Disa, J., Jadhav, V., Lubbers, L. et al. (2016) Silencing myostatin using cholesterol-conjugated siRNAs induces muscle growth. Mol. Ther. Nucleic Acids, 5, e342.
27. Turanov, A.A., Lo, A., Hassler, M.R., Makris, A., Ashar-Patel, A., Alterman, J.F., Coles, A.H., Haraszti, R.A., Roux, L., Godinho, B.M.D.C. et al. (2018) RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat. Biotechnol., doi:10.1038/nbt.4297.
28. DiFiglia, M., Sena-Esteves, M., Chase, K., Sapp, E., Pfister, E., Sass, M., Yoder, J., Reeves, P., Pandey, R.K., Rajeev, K.G. et al. (2007) Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. PNAS, 104, 17204-17209.
29. Deng, Y., Chen, J., Zhao, Y., Yan, X., Zhang, L., Choy, K., Hu, J., Sant, H.J., Gale, B.K. and Tang, T. (2016) Transdermal delivery of siRNA through microneedle array. Sci. Rep., 6, 1-8.
30. Wu, Y., Navarro, F., Lal, A., Basar, E., Pandey, R.K., Manoharan, M., Feng, Y., Lee, S.J., Lieberman, J. and Palliser, D. (2009) Cell host & microbe article durable protection from herpes simplex virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe, 5, 84-94.
31. Alterman, J.F., Hall, L.M., Coles, A.H., Hassler, M.R., Didiot, M.-C., Chase, K., Abraham, J., Sottosanti, E., Johnson, E., Sapp, E. et al. (2015) Hydrophobically modified siRNAs silence Huntingtin mRNA in primary neurons and mouse brain. Mol. Ther. Nucleic Acids, 4, e266.
32. Nikan, M., Osborn, M.F., Coles, A.H., Godinho, B.M., Hall, L.M., Haraszti, R.A., Hassler, M.R., Echeverria, D., Aronin, N. and Khvorova, A. (2016) Docosahexaenoic acid conjugation enhances distribution and safety of siRNA upon local administration in mouse brain. Mol. Ther. Nucleic Acids, 5, e344.
33. Nikan, M., Osborn, M.F., Coles, A.H., Biscans, A., Godinho, B.M., Haraszti, R.A., Sapp, E., Echeverria, D., DiFiglia, M., Aronin, N. et al. (2017) Synthesis and evaluation of parenchymal retention and efficacy of a metabolically stable O-Phosphocholine-N-docosahexaenoyl-l-serine siRNA conjugate in mouse brain. Bioconjug. Chem., 28, 758-1766.
34. Godinho, B.M.D.C., Gilbert, J.W., Haraszti, R.A., Coles, A.H., Biscans, A., Roux, L., Nikan, M., Echeverria, D., Hassler, M. and Khvorova, A. (2017) Pharmacokinetic profiling of conjugated therapeutic oligonucleotides: a high-throughput method based upon serial blood microsampling coupled to Peptide Nucleic Acid hybridization assay. Nculeic Acid Ther., 27, 323-334.
35. Roehl, I., Schuster, M. and Seiffert, S. (2011) Oligonucleotide detection method. US Patent US20110201006A1, 1-9.
36. Coles, A.H., Osborn, M.F., Alterman, J.F., Turanov, A.A., Godinho, B.M., Kennington, L., Chase, K., Aronin, N. and Khvorova, A. (2016) A high-throughput method for direct detection of therapeutic oligonucleotide-induced gene silencing in vivo. Nucleic Acid Ther., 26, 86-92.
37. van Meer, G., Voelker, D.R. and Feigenson, G.W. (2008) Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell Biol., 9, 112-124.
38. Phillips, G.B. and Dodges, J.T. (1967) Composition of phospholipids and of phospholipid fatty acids of human plasma. J. Lipid Res., 8, 676-681.
39. Morrissey, D.V., Blanchard, K., Shaw, L., Jensen, K., Lockridge, J.A., Dickinson, B., McSwiggen, J.A., Vargeese, C., Bowman, K., Shaffer, C.S. et al. (2005) Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology, 41, 1349-1356.
40. Harbort, J., Elbashir, S.M., Vandenburgh, K., H., M., Scaringe, S.A., Weber, K. and Tuschl, T. (2003) Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev., 13, 83-105.
41. Smith, M. and Jungalwala, F.B. (1981) Reversed-phase high performance liquid chromatography of phosphatidylcholine: a simple method for determining relative hydrophobic interaction of various molecular species. J. Lipid Res., 22, 697-704.
42. Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W.S. and Khvorova, A. (2004) Rational siRNA design for RNA interference. Nat. Biotechnol., 22, 326-330.
43. Oberbauer, R., Schreiner, G.F. and Meyer, T.W. (1995) Renal uptake of an 18-mer phosphorothioate oligonucleotide. Kidney Int., 48, 1226-1232.
44. Geary, R.S. (2009) Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin. Drug Metab. Toxicol., 5, 381-391.
45. Reed, D.R., Bachmanov, A.A. and Tordoff, M.G. (2007) Forty mouse strain survey of body composition. Physiol. Behav., 91, 593-600.
46. Wanke, R., Milz, S., Rieger, N., Ogiolda, L., Renner-Müller, I., Brem, G., Hermanns, W. and Wolf, E. (1999) Overgrowth of skin in growth hormone transgenic mice depends on the presence of male gonads. J. Investig. Dermatol., 113, 967-971.
47. Taniguchi, T., Miyauchi, E., Nakamura, S., Hirai, M., Suzue, K., Imai, T., Nomura, T., Handa, T., Okada, H., Shimokawa, C. et al. (2015) Plasmodium berghei ANKA causes intestinal malaria associated with dysbiosis. Sci. Rep., 5, 1-12.
48. Suhr, O.B., Coelho, T., Buades, Pouget, Conceicao, J., Berk, I., Schmidt, J., Waddington-Cruz, H., Campistol, J.M., Bettencourt, B.R. et al. (2015) Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J. Rare Dis., 10, 1-9.
49. Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E.S., Busini, V., Hossain, N., Bacallado, S.A., N., N.D., Fuller, J., Alvarez, R. et al. (2008) A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol., 26, 561-569.
50. Chen, S., Tam, Y.Y.C., Lin, P.J.C., Sung, M.M.H., Tam, Y.K. and Cullis, P.R. (2016) Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. J. Control Release, 235, 236-244.
51. Ansseau, E., Vanderplanck, C., Wauters, A., Harper, S.Q., Coppée, F. and Belayew, A. (2017) Antisense oligonucleotides used to target the DUX4 mRNA as therapeutic approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD). Genes, 8, 1-21.